Vapotherm : Overview

Option 5

Certain statements in this presentation contain or may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could,"' "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue", the negative of these terms or other similar expressions, or the use of future dates, although not all forward-looking statements contain these words. Forward-looking statements may include, but are not limited to, statements regarding: our estimates of the annual total addressable global market for our product and service offerings; our expectations about market trends, new product timing and success, including with respect to the anticipated launch and success of the home product, and our anticipated future operating results. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to the following: Vapotherm has incurred losses in the past and may be unable to achieve or sustain profitability in the future or achieve its 2023 financial guidance including revenue growth, gross margin, cash operating expense reduction, and reduced cash burn; risks associated with its manufacturing operations in Mexico; Vapotherm's ability to raise additional capital to fund its existing commercial operations, develop and commercialize new products, and expand its operations; Vapotherm's ability to comply with its financial covenants, execute on its path-to-profitability initiative, convert excess inventory into cash and fund its business through 2023; Vapotherm's dependence on sales generated from its High Velocity Therapy systems, competition from multi-national corporations who have significantly greater resources than Vapotherm and are more established in the respiratory market; the ability of Vapotherm's present and anticipated products to gain broad market acceptance; Vapotherm's inexperience directly marketing and selling its products; the potential loss of one or more suppliers and dependence on its new third party manufacturer; Vapotherm's susceptibility to seasonal fluctuations; Vapotherm's failure to comply with applicable United States and foreign regulatory requirements; the failure to obtain U.S. Food and Drug Administration or other regulatory authorization to market and sell future products or its inability to secure, maintain or enforce patent or other intellectual property protection for its products; the impact of COVID on its business, including its supply chain, a possible delisting of Vapotherm's common stock and the other risks and uncertainties included under the heading "Risk Factors" in Vapotherm's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on February 23, 2023, and its subsequent filings with the SEC, including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023. The forward-looking statements contained in this press release reflect Vapotherm's views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

The inventor of the heated humidified high flow category

Instrumental in making high flow a standard respiratory support in the acute care hospital setting

1999	2003
Vapotherm Incorporated	A Category is Born
Vapotherm's technology was	Vapotherm releases first
adopted from racehorses for	commercial heated high velocity
clinical use	therapy product to market

2016	2011
Non-inferior to NIPPV	High Flow MOA
Study published in JAMA Pediatrics shows	High flow therapy
high velocity therapy to be non-inferior to	mechanisms of actions
NiPPV for primary respiratory support for	defined
neonates with RDS
2018
Mask-Free NIV	New FDA Category
Study published in Annals of Emergency	FDA clears high velocity therapy
Medicine shows high velocity therapy to be	for expanded indications of use to
non-inferior to NiPPV for adult patients in	treat respiratory distress and/or
undifferentiated respiratory failure	hypoxemia.

2020

Firstline Defense for COVID

Study published in CHEST shows the

dispersion of aerosolized particles from high velocity therapy can be mitigated with a simple surgical mask on the patient.

Vapotherm is present in over 30% of the acute care hospitals in the United States…

Vapotherm

2,000 acute care hospitals in 50 States

Internal data on file